TIBSOVO® (ivosidenib tablets) is a once-daily, oral differentiation therapy for the treatment of adult patients who have a susceptible IDH1 mutation as detected by an FDA-approved test with1,2:
Acute myeloid leukemia 
In combination with azacitidine for newly diagnosed, IC-ineligible AML or as monotherapy for newly diagnosed, IC-ineligible AML and R/R AML2
Cholangiocarcinoma 
For previously treated, locally advanced or metastatic CCA2